Coherus BioSciences Inc (CHRS)vsInsmed Inc (INSM)
CHRS
Coherus BioSciences Inc
$1.71
+4.27%
HEALTHCARE · Cap: $227.83M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1338% more annual revenue ($606.42M vs $42.17M). CHRS leads profitability with a 4.0% profit margin vs -2.1%. CHRS earns a higher WallStSmart Score of 47/100 (D+).
CHRS
Hold47
out of 100
Grade: D+
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 33 in profit
Revenue surging 64.9% year-over-year
No standout strengths identified
Areas to Watch
Smaller company, higher risk/reward
4.0% margin — thin
Earnings declined 75.5%
Negative free cash flow — burning cash
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CHRS
The strongest argument for CHRS centers on Return on Equity, Revenue Growth. Revenue growth of 64.9% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CHRS
The primary concerns for CHRS are Market Cap, Profit Margin, EPS Growth. Thin 4.0% margins leave little buffer for downturns.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CHRS profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
CHRS is growing revenue faster at 64.9% — sustainability is the question.
CHRS generates stronger free cash flow (-20M), providing more financial flexibility.
Bottom Line
CHRS scores higher overall (47/100 vs 39/100) and 64.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coherus BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?